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Abstract
Background: Obstructive sleep apnea (OSA) is associated with increased cardiovascular risk. This study aim to assess
differences in changes in arterial stiffness of two groups of patients, defined as having daytime sleepiness or not, after
continuous positive airway pressure (CPAP) treatment.
Methods: A selected cohort of consecutive male patients, under 65 years old, with moderate to severe OSA and
without great number of comorbidities was studied. The diagnosis was confirmed by home respiratory poligraphy.
Sleepiness was considered with an Epworth Sleepiness Scale (ESS) > 10.
An ambulatory blood pressure (BP) monitoring and carotid-femoral pulse wave velocity (cf-PWV) measurements were
performed, before and after four months under CPAP. Compliant patients, sleepy and non-sleepy, were compared using
linear mixed effects regression models. A further stratified analysis was performed with non-sleepy patients.
Results: Thirty-four patients were recruited, with mean age 55.2 (7.9) years, 38.2% were sleepy, 79.4% with hypertension,
61.8% with metabolic syndrome and 82.4% with dyslipidaemia.
In univariable analysis, cf-PWV was strongly related to systolic BP parameters and age, but also to antihypertensive drugs
(p = 0.030), metabolic syndrome (p = 0.025) and daytime sleepiness (p = 0.004). Sleepy patients had a more severe OSA,
with AHI 44.8 (19.0) vs 29.7 (15.7) events/h (p = 0.018), but sleep study parameters were not associated with cf-PWV
values. On multivariable regression, a significant interaction between time (CPAP) and sleepiness (p = 0.033) was found.
There was a weak evidence of a cf-PWV reduction after CPAP treatment (p = 0.086), but the effects of treatment differed
significantly between groups, with no changes in non-sleepy patients, while in sleepy patients a significant decrease was
observed (p = 0.012).
Evaluating non-sleepy patients group under CPAP therapy, results showed that both higher pulse pressure (p = 0.001)
and lower LDL-cholesterol levels (p = 0.015) at baseline were associated to higher cf-PWV changes.
Conclusions: Patients with daytime sleepiness had a more severe OSA and presented a greater arterial stiffness
improvement after CPAP therapy, independently from age and BP. Besides sleepiness, cf-PWV reduction after CPAP
therapy was mainly associated to CV risk factors, and less to sleep study parameters.
Trial registration: Clinicaltrials.gov NCT02273089 23.10.2014 retrospectively registered.
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Background
Obstructive sleep apnea (OSA) is a disorder characterized
by repeated episodes of upper airway collapse during sleep
[1]. OSA is independently associated with several cardio-
vascular (CV) diseases including hypertension, myocardial
infarction, and stroke [2]. The effects of OSA during sleep,
and especially intermittent hypoxia, may have a predomin-
ant role in the vascular consequences of OSA, in associ-
ation with other mechanisms like oxidative stress,
systemic inflammation, impaired glucose and lipid metab-
olism, endothelial dysfunction and sympathetic activation
[3]. The early detection of individuals at higher risk for
CV disease and their treatment is a priority [4].
The condition of the arterial vessels can be studied by
pulse wave velocity (PWV), that can be used as an index
of arterial distensibility. Arterial PWV describes how fast
a blood pressure (BP) pulse travels from one point to an-
other in an artery. Arterial stiffness is now recognized as
a major driver of CV disease, and it depends mainly on
age and BP. PWV is a well-established procedure for
measuring the arterial stiffness, using arterial tonometry,
at the carotid and femoral artery sites: carotid-femoral
pulse wave velocity (cf-PWV), the gold standard index.
It is a noninvasive biomarker for primary and secondary
CV disease prevention, and can be used as an intermedi-
ate endpoint for CV events [5].
OSA is associated with increased arterial stiffness, with
an improvement after continuous positive airway treat-
ment (CPAP) [6, 7].
However, most of OSA patients remain undiagnosed.
Daytime sleepiness, a symptom of OSA easily identifi-
able, was reported in about 20% of all adults with an
Apnea-Hypopnea Index (AHI) ≥ 5/h, in population based
studies [8, 9]. Daytime sleepiness does not correlate well
with OSA severity parameters and, in its absence, the in-
dication for treatment of OSA is still debatable.
Although non-sleepy patients have an augmented ar-
terial stiffness when compared to non-OSA controls
[10], the very few studies performed did not find a sig-
nificant improvement after CPAP. Studies that assessed
CV risk did not find any benefit either [11].
The aim of this study is to verify if there are differences
in the progression of arterial stiffness in a cohort of pa-
tients with OSA, classified as sleepy and non-sleepy,
undergoing treatment with CPAP for four months.
Methods
Study design and patient recruitment
This is a prospective cohort study conducted between
October 2012 to November 2015. Consecutive patients
referred for snoring or OSA-related symptoms to the
Sleep Outpatient Clinic of a Pneumology Department
were recruited if they were male, younger than 65 years
old, and with moderate to severe OSA (AHI > 15/h) [1].
The exclusion criteria included other sleep disorders
(clinically identified); alcohol abuse; known CV disease
beyond hypertension; and other chronic diseases.
Patients with high levels of fasting glucose performed
an additional oral glucose tolerance test, and excluded if
they were diabetic.
Patients were evaluated monthly for assessment of ef-
fectiveness and compliance to therapy, presence of nasal
complaints, and changes on the equipment. They were ex-
cluded from the study if they were not compliant to CPAP
(using at least mean of 4 h/night) [12], if significant weight
loss (> 5%) occurred, or if there was introduction of new
drugs or emergence of new comorbidities.
A laboratorial evaluation, ambulatory blood pressure
monitoring (ABPM) and cf-PWV measurements were
made before and after 4 months of the beginning of
CPAP therapy.
ABPM was performed with Ambulatory Blood Pressure
- SpaceLabs model 90207®. Patients were considered
hypertensive according ABPM values (current guidelines)
or when they were under antihypertensive medication.
At baseline consultation, the Epworth Sleepiness Scale
(ESS) was applied and patients were classified as sleepy
(ESS > 10) or non- sleepy (ESS ≤ 10) [13]. The comorbid-
ities and drug treatments were registered.
A detailed operational definition and description of
the primary and secondary outcomes assessment can be
found in our previous paper [14]. For ethical reasons,
each patient will act as its own control. The study was
approved by the Ethics Committees of our hospital cen-
ter (reference number 84/2012) and NOVA Medical
School/ Faculdade de Ciências Médicas da Universidade
Nova de Lisboa (number 36/2014/CEFCM). Written in-
formed consent was obtained from all patients.
Sleep study and CPAP titration
The diagnosis of OSA was confirmed by home respira-
tory poligraphy (Embletta® system, Broomfield, USA),
which includes continuous recording from nasal cannu-
lae (pressure and flow), thoracic-abdominal motion,
pulse oximetry, electrocardiogram and body position
sensor. Respiratory events were classified using standard
criteria [15].
All patients performed CPAP titration using an auto-
matic auto-CPAP device (ResMed S9 AutoSet, Califor-
nia, USA) for 3 nights, and subsequent change to CPAP
[16]. After downloading the data from CPAP’s card, the
definite value of CPAP was the amount of pressure that
eliminates events in 95% of sleep time.
Carotid-femoral pulse wave velocity (cf-PWV) study
Assessment of cf-PWV was made using a non-invasive
automatic device (Complior®, Colson, Paris). Measure-
ments were performed in the morning, without prior
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consumption of tea or coffee. The assessment was per-
formed in the supine position, and the values took into
account the concomitant arterial BP [5].
CF-PWV was measured using the «foot-to-foot» vel-
ocity method from the pressure waveforms, obtained
using surface tonometry probes at the right common ca-
rotid artery and the right femoral artery. The time delay
(Dt, or transit time) is measured between the «foot» of
these two waveforms. The distance D covered by the
waves is incorporated to the skin distance the two to-
nometry probes, i.e. the common carotid artery and the
common femoral artery. PWV is estimated as PWV =D/
Dt (m/s) [5].
Statistical analysis
Patients’ characteristics were described using the mean
and standard deviation (SD) for continuous variables,
and frequencies (percentages) for categorical variables.
To compare characteristics of patients before and after
CPAP therapy, Wilcoxon signed rank test and McNemar
test were used. In this analysis, demographic variables,
sleep study parameters, blood tests and vascular parame-
ters were used. Additionally, in order to investigate asso-
ciations between these variables and cf-PWV, linear
mixed effects regression models were applied. All the
variables that attained a p-value ≤0.25 were considered
for the multivariable analysis. As in this analysis an
interaction was identified between ESS group and time
(defined by the two assessment instants: before and after
CPAP), a stratified analysis by ESS group was also per-
formed in order to investigate potential associations be-
tween baseline variables and changes in cf-PWV (Δcf-
PWV = cf-PWV before CPAP- cf-PWV after CPAP). In
this stratified analysis, linear regression models were
only used in the non-sleepy group, attending to the
small sample size of sleepy patients’ group.
The level of significance α = 0.05 was considered. All
data were analyzed using the Statistical Package for the
Social Sciences for Windows 21.0 (IBM Corp. Released
2012. IBM SPSS Statistics for Windows. Armonk, NY:
IBM Corp.) and Stata (StataCorp. 2013. Stata Statistical
Software: Release 13. College Station, TX: StataCorp LP.).
Results
Forty-two patients with moderate to severe OSA were
recruited for this study.
Three patients refused the treatment and five patients
dropped out later due to poor compliance to CPAP
treatment.
The final cohort included 34 patients, 13 (38.2%) pa-
tients with daytime sleepiness, 19 (55.9%) patients with
moderate OSA and 15 with severe OSA. Clinical charac-
teristics of patients and home respiratory poligraphy
data are shown in Table 1.
Most patients (27; 79.4%) were hypertensive; 6/27
(22.2%) had no treatment and 21/27 (77.8%) were under
antihypertensive medication. In 14/27 (51.9%) patients
BP was uncontrolled; 10/21 (47.6%) patients were on
monotherapy, 7/21 (33.3%) and 4/21 (19.0%) patients
were on two or three antihypertensive drugs, respect-
ively. Dyslipidaemia was highly prevalent, as well as
metabolic syndrome (MetS) [17].
Effects of CPAP
After four months of CPAP, there was a significant de-
crease of ESS (p ≤ 0.001). Regarding AHI, there was also
a significant decrease (p < 0.001) (Table 1), with a mean
compliance to CPAP treatment of 5.7 (1.1) hours, and a
mean pressure of CPAP 9.3 (0.2).
There was an improvement in some metabolic param-
eters, namely total cholesterol (p = 0.021) and LDL-
cholesterol (p = 0.031). After treatment with CPAP there
was a non-significant decrease in dyslipidaemia preva-
lence (p = 0.125) (Table 1).
There was also an improvement in BP parameters,
with a decrease in 24 h diastolic BP (DBP) (p = 0.004),
daytime DBP (p = 0.001) and 24 h mean BP (MBP) (p =
0.030), and with an increase in pulse pressure (p =
0.050). Non-dipping prevalence in 24 h BP evaluation
decreased from 7 (20.6%) to 5 (14.7%) patients, without
significance (p = 0.500).
Also, a weak evidence of a decrease of cf-PWV values
was found (p = 0.086) (Table 1). Although without statis-
tical significance, the prevalence of normal cf-PWV
(<10 m/s) increased from 5/34 (14.7%) to 9/34 (26.5%)
patients (p = 0.289).
Parameters related to cf-PWV
In univariable analysis there was an association between
age, ESS, 24 h SBP, daytime SBP, night-time SBP, pulse
pressure, the use of antihypertensive drugs and the pres-
ence of MetS with higher values of cf-PWV (Table 2).
Relating to the group of patients with MetS and com-
paring to the patients without MetS, there was a higher
prevalence of hypertension (p = 0.004) and antihiperten-
sive drugs (p < 0.001). Triglycerides (p = 0.002) and glu-
cose (p = 0.003) levels were higher, but presented lower
HDL-cholesterol levels (p = 0.004) and lower mean
SaO2 (p = 0.002).
Moreover, levels of cf-PWV were higher than in pa-
tients without MetS, both at baseline (p = 0.04) and fol-
low up (p = 0.04).
Results of the multivariable regression model showed
an association between ESS group and cf-PWV after
adjusting by age, pulse pressure and time.
The final multivariable linear mixed regression model
(Table 3), after taking into account the coefficient esti-
mate of the interaction term, revealed a different effect
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of CPAP in the two groups of patients, with a more signifi-
cant reduction from baseline in cf-PWV in sleepy
(1.31 m/s) than in non-sleepy (0.24 m/s) patients. Regard-
ing ESS group, still considering the coefficient estimate of
the interaction term, a higher cf-PWV difference between
the two groups exists at baseline (1.23 m/s) when com-
pared to four months later values (0.15 m/s) (Fig. 1).
Moreover, for each increase of 1 year of age there was
a cf-PWV mean increase of 0.07 m/s, and for each mm
Hg increase in pulse pressure there was a cf-PWV mean
increase of 0.16 m/s.
Stratified analysis by sleepy and non-sleepy patients
At baseline, sleepy patients had higher AHI than their
counterparts, with 44.8 (19) events/h vs 29.7 (15.7)
events/h (p = 0.018). No differences were found in
age, BMI, or metabolic parameters between these two
groups. There was also no difference in the preva-
lence rates of BP, antihipertensives or lipid lowering
drugs (Table 4).
After treatment with CPAP, and regarding cf-PWV,
there was a significant decrease in sleepy patients
Table 1 Demographic and clinical characteristics of patients
before and after CPAP therapy (n = 34)
Variables Before CPAP After CPAP p-value
Age 55.2 (7.9) – –
BMI 31.2 (4.1) 31.3 (4.0) 0.901
Smoking 7 (20.6) – –
ESS >10 8.4 (4.3) 4.8 (2.7) <0.001*
AHI (events/h) 35.2 (18.8) 2.6 (2.3) <0.001
ODI (events/h) 25.5 (20.0) – –
Mean SaO2 (%) 92.1 (2.1) – –
Lower SaO2 (%) 79.8 (8.5) – –
SaO2 < 90% (%) 17.7 (18.5) – –
Total cholesterol, mg/dl 198.2 (32.9) 187.4 (36.0) 0.021
HDL-cholesterol, mg/dl 44.3 (10.3) 44.5 (11.0) 0.678
LDL-cholesterol, mg/dl 131.0 (29.4) 121.5 (30.8) 0.031
Triglycerides, mg/dl 137.9 (51.0) 126.6 (59.6) 0.124
Glucose, mg/dl 98.7 (12.8) 98.2 (11.7) 0.924
HbA1c, % 5.7 (0.4) 5.8 (0.4) 0.064
24 h SBP (mm Hg) 129.8 (10.5) 128.0 (10.3) 0.287
24 h DBP (mm Hg) 82.4 (7.1) 79.2 (6.4) 0.004
Pulse pressure (mm Hg) 47.4 (7.3) 48.8 (8.1) 0.050
24 h MBP (mm Hg) 97.4 (7.9) 94.9 (7.2) 0.030
Day-time SBP (mm Hg) 133.3 (10.5) 131.2 (10.9) 0.214
Day-time DBP (mm Hg) 85.4 (7.3) 81.6 (6.9) 0.001
Night-time SBP (mm Hg) 117.9 (12.6) 116.4 (9.5) 0.363
Night-time DBP (mm Hg) 72.1 (9.1) 70.1 (5.9) 0.169
Hypertension n (%) 27 (79.4) 25 (73.5) 0.500*
Antihypertensive drugs, n (%) 21 (61.8) – –
Dyslipidaemia n (%) 28 (82.4) 24 (70.6) 0.125*
Lipid lowering drugs n (%) 14 (41.2) – –
MetS n (%) 21 (61.8) 20 (58.8) 1.000*
Cf-PWV (m/s) 12.3 (2.3) 11.7 (1.8) 0.086
Results are expressed as mean (standard deviation); *p-values obtained by
McNemar test; remaining p-values were obtained by Wilcoxon rank exact test
CPAP continuous positive airway treatment, BMI Body mass index, ESS Epworth
Sleepiness Scale, AHI Apnea/Hypopnea Index, ODI Oxygen Desaturation Index,
SaO2 arterial oxygen saturation, HbA1c glycated haemoglobin, SBP systolic
blood pressure, DBP diastolic blood pressure, MetS metabolic syndrome,
cf-PWV carotid-femoral pulse wave velocity
Table 2 Univariable regression analysis for cf-PWV
Variables Coefficient estimate (95% CI) p-value
Time −0.52 (−1.06; 0.02) 0.057
Age 0.11 (0.04; 0.02) 0.002
BMI 0.01 (−0.14; 0.17) 0.899
Smoking −0.47 (−2.05; 1.11) 0.561
ESS 0.13 (0.04; 0.23) 0.004
ESS >10 −0.15 (−1.47; 1.17) 0.822
AHI (events/h) 0.01 (−0.03; 0.04) 0.725
ODI (events/h) 0.01 (−0.03; 0.04) 0.705
Mean SaO2 (%) −0.06 (−0.37; 0.26) 0.730
Lower SaO2 (%) 0.04 (−0.04; 0.11) 0.366
SaO2 < 90% (%) −0.002 (−0.04; 0.03) 0.917
CPAP compliance −0.09 (−0.67; 0.48) 0.752
Total cholesterol, mg/dl −0.002 (−0.02; 0.02) 0.794
HDL-cholesterol, mg/dl −0.05 (−0.10; 0.01) 0.127
LDL-cholesterol, mg/dl −0.01 (−0.03; 0.01) 0.554
Triglycerides, mg/dl 0.01 (−0.00; 0.02) 0.168
Glucose, mg/dl 0.02 (−0.01; 0.05) 0.229
HbA1c, % 0.41 (−0.076; 1.59) 0.490
24 h SBP (mm Hg) 0.09 (0.04; 0.14) <0.001
24 h DBP (mm Hg) 0.05 (−0.01; 0.12) 0.109
Pulse pressure (mm Hg) 0.15 (0.08; 0.21) <0.001
24 h MBP (mm Hg) 0.04 (−0.02; 0.10) 0.224
Day-time SBP (mm Hg) 0.09 (0.04; 0.13) <0.001
Day-time DBP (mm Hg) 0.04 (0.02; 0.11) 0.167
Night-time SBP (mm Hg) 0.07 (0.03; 0.11) 0.002
Night-time DBP (mm Hg) 0.05 (−0.01; 0.11) 0.109
Hypertension 1.29 (−0.24; 2.81) 0.099
Antihypertensive drugs 1.37 (0.13; 2.61) 0.030
Dyslipidaemia 0.49 (−1.19; 2.17) 0.569
Lipid lowering drugs 0.22 (−1.09; 1.52) 0.745
MetS 1.44 (0.18; 2.70) 0.025
CPAP continuous positive airway treatment, BMI Body mass index, ESS Epworth
Sleepiness Scale, AHI Apnea/Hypopnea Index, ODI Oxygen Desaturation Index,
SaO2 arterial oxygen saturation, HbA1c glycated haemoglobin, SBP systolic
blood pressure, DBP diastolic blood pressure, MetS metabolic syndrome, cf-
PWV carotid-femoral pulse wave velocity, p-values were obtained by linear
mixed effects regression models
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(p = 0.012) and a non-significant decrease in non-sleepy
patients (p = 0.779).
In non-sleepy patients, the change in cf-PWV after
four months of CPAP was associated most strongly with
pulse pressure (coefficient estimate = 0.08 m/s; 95% CI,
0.01 to 0.15, p = 0.034) (Additional file 1).
Also, there was a weak association between cf-PWV
change with triglycerides (coefficient estimate = 0.01 m/
s; 95% CI, −0.00 to 0.03, p = 0.080), and with the pres-
ence of lipid lowering drugs (coefficient estimate =
1,23 m/s; 95% CI, −0.09 to 2.56, p = 0.066).
To identify the associated variables with cf-PWV
changes between baseline and after four months of
CPAP therapy, multiple linear regression analysis was
performed, revealing that higher pulse pressure was as-
sociated with higher cf-PWV changes and higher LDL-
cholesterol levels were associated with lower cf-PWV
changes (Table 5).
Discussion
This study is the first to attempt to identify characteris-
tics of sleepy and non-sleepy patients that might justify
the different effects of CPAP on arterial stiffness.
Selecting a cohort of male patients with moderate to
severe OSA and without a great number of comorbidi-
ties, we found a high prevalence of hypertension, dyslipi-
daemia and MetS.
After four months of CPAP treatment there was an
improvement in 24 h DBP, daytime DBP, and levels of
total cholesterol. Age and SBP were variables associated
to cf-PWV, as expected, but daytime sleepiness was also
detected. In multivariable analysis, we found that sleepy
and non-sleepy groups behaved differently, under CPAP
treatment. In the fitted model, sleepiness was an inde-
pendent determinant of the longitudinal decrease in cf-
PWV (p = 0.033 for interaction with time), after adjust-
ing for covariates, meaning time, age and pulse pressure.
Analysing the subgroup of non-sleepy patients, a high
pulse pressure and lower levels of LDL cholesterol were
predictive of higher cf-PWV changes, in a model where
71% of cf-PWV variability was explained by those inde-
pendent variables.
The strengths of our study settled, thus, in the use of a
standardized marker of vascular disease and stiffness (cf-
PWV), and the evaluation of CPAP compliant patients.
There are at least two meta-analysis [6, 7] identifying a
decrease in arterial stiffness after CPAP treatment in pa-
tients with OSA, and in patients with OSA and hyper-
tension; only four from the selected studies evaluated
the effect on cf-PWV.
The effect of CPAP reducing cf-PWV was well de-
scribed in studies with highly selected samples, including
very severe and younger OSA patients [18, 19], or less
obese patients [20] than those that we recruited, and this
is due to the absence of comorbidities, namely hyperten-
sion. Also, in those studies patients were mainly symp-
tomatic and sleepy.
Kohler et al. [21] studied 208 patients less symptom-
atic, with ESS 8.4 (4), and found that, after six months
of CPAP, arterial stiffness (measured by AIx) did not im-
prove, compared to controls. However, patients included
in that study had a milder OSA than ours and the me-
dian compliance of CPAP was 2.8 h per night. Moreover,
in the subgroup with higher compliance there were not
significant changes in arterial stiffness, either.
In contrast with these results, in a meta-regression
analysis examining the effect of potential modifiers upon
the effect of CPAP on arterial stiffness, the sleepiness
score did not have significance [6].
We admit that the role of sleepiness as well as the use-
fulness of cf-PWV measurements may be best defined in
this sample under 60 years old and without a great num-
ber of comorbidities, yet very prevalent in the clinical set.
Concerning the improvement in lipid profile, our re-
sults are in agreement with the meta-analysis results of
Nadeem et al. CPAP treatment seems to improve dysli-
pidaemia, although we did not find an increase in HDL-
cholesterol as described [22].
MetS was associated to higher levels of cf-PWV, but it
was not included in the multivariable regression model.
Patients with MetS were found to have significantly
Table 3 Multivariable regression analysis for cf-PWV
Variables Coefficient estimate (95%CI) p-value
Age 0.07 (0.01; 0.13) 0.015
Time −0.24 (−0.89; 0.41) 0.470
Pulse pressure (mm Hg) 0.16 (0.10; 0.21) <0.001
ESS >10 1.23 (0.18; 2.27) 0.022
Time×ESS* −1.07 (−2.05; −0.09) 0.033
ESS Epworth Sleepiness Scale; *interaction term of ESS group and time
(defined by the two assessment instants: before and after CPAP); p-values
were obtained by linear mixed effects regression models
Fig. 1 Interaction between ESS group and time regarding cf-PWV
measurements. Time: 1-before CPAP; 2- after CPAP. Sleepy group:
ESS > 10; non-sleepy group: ESS≤ 10. ESS- Epworth Sleepiness Scale
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higher baseline and follow up levels of cf-PWV than pa-
tients without MetS, besides a more severe OSA defined
by lower mean SaO2 levels. In fact, MetS is an additive
factor to arterial wall damage and only in very selected
populations it has been possible to demonstrate a
reduction of some of the syndrome components or its
prevalence [23].
We found, among the variables selected, that pulse pres-
sure was positively related to cf-PWV values, as well as
SBP parameters. In the non-sleepy group analysis pulse
pressure was predictive of greater cf-PWV changes, and
other BP variables were excluded from the model.
The predominant association of pulse pressure with
cf-PWV variations is interesting as it is probably related
to early vascular ageing of OSA patients. Pulse pressure
has showed the strongest association with aortic cf-
PWV over other haemodynamic BP parameters, namely
Table 4 Demographic and clinical characteristics of patients before and after CPAP therapy by ESS group
Sleepy (n = 13) Non-sleepy (n = 21)
Variables Before CPAP After CPAP Before CPAP After CPAP
Age 55.08 (6.2) – 55.19 (9.0) –
BMI 31.5 (3.6) 31.1 (3.4) 31.1 (4.4) 31.3 (4.5)
Smoking, n (%) 2 (15.3%) – 5 (23.8%) –
ESS# 13 (1.8)* 5.9 (3.3)* 5.5 (2.4)* 4.1 (2.0)*
AHI (events/h)# 44.8 (19.0)* 4.0 (3.0)* 29.7 (15.7)* 1.9 (1,2)*
ODI (events/h)# 35.8 (21.4) – 19.2 (16.6) –
Mean SaO2 (%) 91.2 (2.4) – 92.6 (1.7) –
Lower SaO2 (%)
# 71 (7.6) – 77.1 (8.3) –
SaO2 < 90% (%)
# 26.9 (22.8) – 12.1 (12.7) –
Total chol, mg/dl 199.4 (34.0) 188.4 (42.5) 200.5 (34.3) 186.5 (30.5)
HDL-cholesterol, mg/dl 44.7 (12.0) 44.8 (12.1) 44.0 (9.1) 44.3 (10,3)
LDL-cholesterol, mg/dl 128.3 (31.6) 122.5 (33.1) 135.4 (28.6)* 120.6 (30.0)*
Triglycerides, mg/dl 117.7 (37.7) 120.1 (64.4) 154.3 (56.0) 132.1 (56.9)
Glucose, mg/dl 101.4 (11.8) 97.2 (13.9) 96.8 (13.1) 98.9 (10.2)
HbA1c, % 5.7 (0.4) 5.9 (0.4) 5.7 (0.4) 5.8 (0.3)
24 h SBP (mm Hg) 128.8 (9.8) 125.0 (9.2) 130.6 (11.2) 130.3 (10.8)
24 h DBP (mm Hg) 83.7 (7.7)* 78.7 (5.9)* 81.5 (6.7) 79.6 (6.9)
Pulse pressure (mm Hg) 45.2 (4.6) 46.3 (6.9) 49.1 (8.6) 50.7 (8.7)
24 h MBP (mm Hg) 97.9 (8.5)* 92.8 (6.4)* 97.1 (7.6) 96.4 (7.5)
Dt SBP (mm Hg) 133.3 (9.4) 127.6 (9.5) 134.8 (11.6) 133.9 (11.3)
Dt DBP (mm Hg) 86.5 (7.8)* 80.9 (6.4)* 84.5 (7.1)* 82.1 (7.4)*
Nt SBP (mm Hg) 117.8 (11.9) 116.7 (9.5) 118.0 (13.4) 116.1 (9.8)
Nt DBP (mm Hg) 74.1 (9.2) 71.0 (5.7) 70.7 (9.1) 69.4 (6.2)
Hypertension, n (%) 11 (84.6%) – 16 (76.2%) –
Hypertensive drugs, n (%) 8 (61.5%) – 13 (61.9%) –
Dyslipidemia, n (%) 11(84.6%) – 17 (81.0%) –
Lipid lowering drugs, n (%) 5 (38.5%) – 9 (42.9%) –
MetS n (%) 8 (61.5%) – 14 (66.7%) –
cf-PWV (m/s) 12.5 (1.9)*§ 11.3 (1.6)* 12.1 (2.6)£ 12.04 (2.0)
Results are expressed as mean (standard deviation); ESS Epworth Sleepiness Scale, AHI apnea/hypopnea index, ODI oxygen desaturation index, SaO2 arterial
oxygen saturation, SaO2 < 90% time under 90%, HDL high density lipoprotein, LDL low density lipoprotein, SBP systolic blood pressure, DBP diastolic blood
pressure, Dt day-time, Nt night-time, MetS metabolic syndrome, cf-PWV carotid-femoral pulse wave velocity; #p < 0.05 comparison between sleepy and non-sleepy
groups, at baseline (Mann-Whitney test); *p < 0.05 comparison between before and after CPAP, in each ESS group (Wilcoxon signed rank test), for cf-PWV (m/s): §p
= 0.012; £p = 0.779, in sleepy and non-sleepy group, respectively
Table 5 Results of multivariable model corresponding to cf-PWV
changes among 21 patients without daytime sleepiness
Variables Coefficient estimate (95%CI) p-value
Pulse pressure (mm Hg) 0.13 (0.07; 0.19) 0.001
LDL-cholesterol (mm Hg) −0.03 (−0.05; −0.01) 0.015
LDL low density lipoprotein. Overall model adjusted R2 = 0.71
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from age 60 years and over, where it begins to increase
precipitously. In OSA patients, Sanner et al. also found
that a higher pulse pressure before treatment with CPAP
was predictive of a beneficial CPAP effect on BP, over
other BP parameters [24].
In the sleepy group of patients and after adjusting for
age and pulse pressure, there was a reduction of cf-PWV
of 1.31 m/s from baseline. Also, and though there was
no difference between groups, we found a difference
among them of 0.15 m/s, after CPAP therapy.
This is relevant as an increase in aortic PWV by 1 m/s
is known to correspond to an age-, sex-, and risk factor-
adjusted risk increase of 14%, 15%, and 15% in total CV
events, CV mortality, and all-cause mortality, respect-
ively [25].
Patients with daytime sleepiness tend to experience
more severe OSA [26], and the severity of OSA could in-
fluence the results of CPAP therapy. In this study, the
group of sleepy patients has higher AHI, ODI and SaO2
< 90% than the non-sleepy patients. However, sleep
study parameters were not correlated to cf-PWV
changes, neither predictive of a better outcome in non-
sleepy group of patients.
The issue of sleepiness as an independent variable was
raised in studies on OSA and hypertension [27]. CPAP
significantly reduces BP in patients with OSA but with a
low effect size [28]. When non-sleepy/less symptomatic
patients were evaluated, a DBP reduction of less than
1 mmHg was found in compliant patients and may be
significant, but its clinical meaning is debatable [11].
Daytime sleepiness was also identified as independent
variable predicting BP changes in patients with OSA
under CPAP [29].
In our study, non-sleepy patients had a mean compli-
ance of 5.9 (0.22) hours, and a significant reduction of
2.4 mmHg occurred in daytime DBP.
Regarding the mechanisms involved in the pathophysi-
ology of daytime sleepiness, some studies suggest that it
is related to sleep fragmentation [30], while others have
found an association with both nocturnal hypoxemia
[31] and changes produced by intermittent hypoxemia.
One possible explanation for our findings is based in
the knowledge that daytime sleepiness is related to both
the systemic inflammation associated with sleep disrup-
tion (sleep fragmentation and arousals) and to the sever-
ity of nocturnal desaturation, which appears to be the
primary proatherogenic feature of OSA [32]. It may thus
represent the global effect of OSA severity factors.
Study limitations
Limitations of this study were the small sample size,
though it was not an obstacle for the general aim, and
the lack of a control group, which makes this study
mainly hypothesis generating. The results cannot be
extended to women, the elderly or patients with comor-
bidities. The use of polysomnography instead of home
respiratory poligraphy would allow a more complete
evaluation of associations between sleep variables and
cf-PWV changes, although it was time consuming and
uncomfortable for patients with active working life.
Conclusions
In a cohort of consecutive middle aged men with moder-
ate to severe OSA, mainly with metabolic syndrome and
dyslipidaemia, it was found a significant decrease in cf-
PWV, in sleepy but not in non-sleepy patients. In non-
sleepy patients, pulse pressure and LDL-cholesterol at
baseline were predictive of higher cf-PWV changes. Fur-
ther studies are needed to confirm the use of cf-PWV as a
biomarker of response to CPAP therapy in OSA patients
with sleepiness and good compliance to the treatment.
Additional file
Additional file 1: Table S1. Univariable regression analysis investigating
associations between variables and Δcf-PWV, in non-sleepy patients.
(DOCX 13 kb)
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